Outcome of the Board Meeting

spare SPARC/Sec/SE/2026-27/26 August 10, 2026 National Stock Exchange of India Ltd., BSE Limited, Exchange Plaza, 5th Floor, Market Operations Dept. Plot No. C/1, G Block, P. J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 051. Mumbai - 400 001. Scrip Symbol: SPARC Scrip Code: 532872 Dear Sir/ Madam, Sub: Outcome of the Board Meeting held today i.e. on August 10, 2026 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we hereby intimate that the Board of Directors of the Company at its meeting held today i.e. on August 10, 2026, inter alia, 1. Approved the Unaudited Financial Results for the quarter ended June 30, 2026 The Unaudited Standalone and Consolidated Financial Results for quarter ended June 30, 2026, as approved pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) along with the Limited Review Report, are annexed herewith as Annexure A. 2. Approved the requests for reclassification of certain promoter group individuals Further to our intimation dated July 27, 2026, the requests received for reclassification from the “Promoter Group” category to the “Public” category is approved, subject to receipt of necessary approvals as prescribed under the Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The meeting of the Board of Directors of the Company commenced at 11:00 AM (IST) and concluded 01:10 PM (IST). This is for your information and dissemination. For Sun Pharma Advanced Research Company Limited. Kajal Damania Company Secretary and Compliance Officer Encl: As above SunPharmaAdvancedResearchCompanyLtd. 17/B,MahalIndustrialEstate,OffMahakaliCavesRoad,Andheri(East),Mumbai400093,Maharashtra,India. Tel.:(91-22)66455645 |Fax.:(91-22)66455685|CIN:L73100GJ2006PLC047837|Website:www.sparc.life Registeredoffice:Plotno.5&6/1,SavliGIDCEstate,Manjusar391775,District:Vadodara,Gujarat,India. SRBC&CO LLP GroundFloor PanchshilTechPark,Yerwada CharteredAccountants (NearDonBoscoSchool) Pune-411006,India Tel :+912066036000 Independent Auditor'sReview Report on the Quarterly Unaudited StandaloneFinancial Results of the CompanyPursuantto theRegulation33 of theSEBI(ListingObligationsandDisclosureRequirements) Regulations,2015,as amended ReviewReport to TheBoardof Directors SunPharma AdvancedResearch CompanyLimited 1. Wehavereviewedtheaccompanyingstatement of unaudited standalone financial results of Sun Pharma AdvancedResearchCompany Limited(the "Company") for the quarter endedJune30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,asamended(the"ListingRegulations"). 2. The Company's Management is responsible for the preparation of the Statement in accordance withtherecognitionandmeasurementprincipleslaiddowninIndianAccountingStandard34,(Ind AS 34)"InterimFinancialReporting”prescribed under Section 133 of theCompanies Act, 2013 asamended,readwithrelevantrulesissuedthereunderandotheraccountingprinciplesgenerally acceptedinIndiaandincompliancewithRegulation33of theListingRegulations.TheStatement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusionontheStatement based onourreview. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, "Review of Interim Financial Information Performed by the Independent Auditor of theEntity"issuedby theInstituteof CharteredAccountantsof India.This standard requires that we plan and perform the review to obtain moderate assurance as to whethertheStatement isfreeof materialmisstatement.Areviewofinterimfinancialinformation consistsof makinginquiries,primarilyofpersonsresponsibleforfinancialandaccountingmatters, and applyinganalytical andother review procedures. A review issubstantiallylessinscopethan anaudit conductedinaccordance withStandardson Auditingand consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identifiedinanaudit. Accordingly,we donot express anaudit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act,2013 as amended, read with relevant rules issued thereunder andother accounting principles generally acceptedinIndia, has not disclosed theinformationrequiredtobedisclosedintermsof theListingRegulations,includingthemanner in whichit istobedisclosed,or that it containsanymaterialmisstatement. ForS R B C &CO LLP Chartered Accountants ICAIFirmregistrationnumber:324982E/E300003 per Amit Singh Partner MembershipNo.:408869 Place:Mumbai Date: August 10,2026 5RBCACOLLP.aLimitedLidtKttyPartnership LLPIdentityNo AAB4318 Regd Office 22.CannaeStreet,BixkB 3rdFloor.Kofxata-700016 Sun Pharma AdvancedResearchCompanyLimited Regd.Office:PlotNo.5& 1,Savli,G.I.D.C.Estate,Savli-VadodaraHighway, Manjusar,Vadodara-391775.Tel.:+91-2667666800 CIN:L73100GJ2006PLC047837.Website:www.sparc.life Statementof UnauditedStandaloneFinancialResultsfor theQuarterEndedJune30,2026 ?inLakhs Quarterended Yearended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Unaudited Audited Unaudited Audited Revenuefromoperations Revenuefromcontractswithcustomers(ReferNote3) 3,992 1,320 964 3,915 Otheroperatingrevenue(ReferNote4) - 1,84,002 - 1,84,002 Totalrevenuefromoperations 3,992 1,85,322 964 1,87,917 Otherincome 2,366 180 902 1,083 Totalincome 6,358 1,85,502 1,866 1,89,000 Expenses Costofmaterialsconsumed 766 516 513 2,360 Employeebenefitsexpense 2,416 2,108 2,768 10,185 Clinicaltrialexpenses/productsdevelopmentexpense 1,326 284 554 2,266 Professionalcharges 2,124 3,480 1,436 8,753 Financecosts 813 1,164 618 3,412 Depreciationandamortisationexpense 220 240 254 1,007 Otherexpenses 791 1,640 926 4,568 Totalexpenses 8,456 9,432 7,069 32,551 Profit/(loss)beforeexceptionalitemandtax (2,098) 1,76,070 (5,203) 1,56,449 Exceptionalitem(ReferNote2) - - - 1,236 Profit/(loss)beforetax (2,098) 1,76,070 (5,203) 1,55,213 Taxexpense - - - - Profit/(loss)fortheperiod (2,098) 1,76,070 (5,203) 1,55,213 Othercomprehensiveincome(OCI) Itemsthatwillnotbereclassifiedtoprofitorloss(netactuarialgain/ - 107 (6) 207 (loss)onemployeedefinedbenefitplan) Totalcomprehensiveprofit/(loss)fortheperiod (2,098) 1,76,177 (5,209) 1,55,420 Paid-upequitysharecapital(Facevalue71each) 3,245 3,245 3,245 3,245 Otherequity 1,30,113 Basicanddilutedearning1(loss)perequityshareof?1each (0.65) 54.26 (1-60) 47.83 Notannualised Notannualised Notannualised Annualised Seeaccompanyingnotestotheunauditedstandalonefinancialresults INITIAL FOR IDENTIFICATION SRBC & CO LLP SunPharma AdvancedResearchCompany Limited Regd.Office:PlotNo.5&6/1,Savli,G.I.D.C.Estate,Savli-VadodaraHighway, Manjusar,Vadodara 391775.Tel.:+91-2667666800 CIN:L73100GJ2006PLC047837.Website:www.sparc.life StatementofUnauditedStandalone Financial Resultsfor theQuarter EndedJune30,2026 Notes: 1 The above unaudited standalonefinancial resultsof SunPharmaAdvancedResearchCompanyLimited (the'Company1) havebeen prepared in accordancewiththeCompanies(IndianAccountingStandards)Rules,2015(IndAS)asamended,prescribedundersection133oftheCompanies Act,2013,readwithrelevantrulesissuedthereunderandaspertheRegulation33oftheSEBI(ListingObligationsandDisclosureRequirements) Regulations, 2015, as amended andhave been taken on record by the Board of Directors at its meeting heldon August 10,2026 after being reviewedbytheAuditCommittee. 2 TheGovernmentofIndiahadconsolidated29existinglabourlegislationsintoaunifiedframeworkcom [Showing first 8,000 characters — download PDF for full document]